Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IDXX with free AI briefings, catalyst countdowns, and dilution alerts.

IDXX · IDEXX LABORATORIES INC /DE

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$197.5M Cash on Hand
CF+ Cash Runway
Follow IDXX by email Get an email when IDXX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IDXX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

IDXX holds $197.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IDXX files for a raise →

👥 Who Owns IDXX

Insiders 0.2% Institutions (1837 holders) 94.6% Public and other holders 5.2%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 5,976,472 7.59% 2026-03-31
Vanguard Portfolio Management Institution (13G, 5%+) 3,974,472 5.04% 2026-09-30
Jonathan Jay Mazelsky
Executive Chair of the Board, Director · +1,099 options
Insider 83,803 0.11% 2026-11-04
Nimrata Hunt
Executive Vice President · +4,787 options
Insider 18,301 0.02% 2026-03-03
Michael G Erickson
Executive Vice President · +13,829 options
Insider 15,092 0.02% 2026-02-17
George Fennell
Executive Vice President · +3,546 options
Insider 12,182 0.02% 2026-11-10
Lawrence D Kingsley
Director · +243 options
Insider 9,568 0.01% 2026-09-04
Sophie V. Vandebroek
Director · +759 options
Insider 9,078 0.01% 2026-05-07
Sharon E. Underberg
EVP, GC & Corporate Secretary · +4,695 options
Insider 7,169 0.01% 2026-11-04
Michael Lane
Executive Vice President · +6,125 options
Insider 4,668 0.01% 2026-11-04
Andrew Emerson
EVP, CFO and Treasurer · +5,938 options
Insider 4,421 0.01% 2026-08-20
Michael Schreck
Executive Vice President · +4,787 options
Insider 3,089 0.00% 2026-02-12

Share count 78,786,265 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IDXX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IDXX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.